TRAVERE THERAPEUTICS INC. - COMMON STOCK

21.62

07-February-25 12:51:47

15 minutes delayed

Stocks

-0.24

-1.10%

Today's range

21.49 - 22.25

ISIN

N/A

Source

NASDAQ

Travere Therapeutics to Report Second Quarter 2024 Financial Results

25 Jul 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

08 Jul 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Jun 2024 16:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 May 2024 16:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

09 May 2024 15:30:56 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

08 May 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports First Quarter 2024 Financial Results

06 May 2024 15:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Report First Quarter 2024 Financial Results

29 Apr 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

24 Apr 2024 06:05:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

04 Apr 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

03 Apr 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Mar 2024 16:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

11 Mar 2024 06:05:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

26 Feb 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

23 Feb 2024 06:05:39 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

15 Feb 2024 15:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

08 Feb 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

01 Feb 2024 15:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

25 Jan 2024 15:05:00 By Nasdaq GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2024 Outlook

08 Jan 2024 06:00:01 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.